CORDIS
EU research results

CORDIS

English EN

Efficacious vaccine formulation system for prophylactic control of influenza pandemics

Project information

Grant agreement ID: 44115

  • Start date

    1 January 2007

  • End date

    30 June 2011

Funded under:

FP6-POLICIES

  • Overall budget:

    € 4 617 050

  • EU contribution

    € 3 334 798

Coordinated by:

FEDERAL VETERINARY OFFICE (FVO) OF THE FEDERAL DEPARTMENT OF ECONOMIC AFFAIRS (FDEA)

Switzerland

Objective

Influenza epidemics remain a burden to both human heath and national economies, as witnessed by the recent advance of pathogenic avian H5N1 influenza virus. While the numbers of human deaths in Europe have remained relatively low, the presence of such cases in Turkey demonstrates the danger posed by this virus. Now that the avian H5N1 has been detected in wild birds in numerous European countries, the PANFLUVAC consortium is committed to creating an efficacious vaccine against this virus, to provide strong protection in a pandemic situation.

The overall aim of PANFLUVAC is to construct vaccine delivery systems for intranasal and parenteral vaccines. New H5N1 vaccines are to be based on well-established virosome technology - proven its worth for efficacious interpandemic vaccines - as well as whole virus vaccines. This will permit comparison of the intranasal virosomal vaccine with whole virus vaccine. The vaccine potency will be enhanced by novel adjuvants targeting dendritic cells, offering both antigen spa ring potential and immunopotentiation characteristics. Both ISCOMs and lipopeptide adjuvants are already proven immunopotentiators, biosafe for humans. Certain of these have been employed with experimental influenza vaccines, which allows the new H5N1 vaccines to be fast-tracked in their development. Accordingly, PANFLUVAC will generate the first H5N1 vaccine within the first 18 months of the project.

The PANFLUVAC project is also designed to facilitate rapid modification of the vaccine in the face of virus drift. Within the pre-clinical evaluation, the new vaccines will be tested for the degree of heterotypic cross protection they offer. PANFLUVAC offers a generic vaccine development system to provide safe and efficacious vaccines against influenza, fitting with the "Community Influenza Pandemic Preparedness and Response Planning".

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

FEDERAL VETERINARY OFFICE (FVO) OF THE FEDERAL DEPARTMENT OF ECONOMIC AFFAIRS (FDEA)

Address

Schwarzenburgstrasse 155
Bern

Switzerland

Participants (7)

CRUCELL N.V.

Netherlands

RETROSCREEN VIROLOGY LTD

United Kingdom

UNIVERSITETET I BERGEN

Norway

HEALTH PROTECTION AGENCY

United Kingdom

ISTITUTO SUPERIORE DI SANITA'

Italy

HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH

Germany

SCIPROM SARL

Switzerland

Project information

Grant agreement ID: 44115

  • Start date

    1 January 2007

  • End date

    30 June 2011

Funded under:

FP6-POLICIES

  • Overall budget:

    € 4 617 050

  • EU contribution

    € 3 334 798

Coordinated by:

FEDERAL VETERINARY OFFICE (FVO) OF THE FEDERAL DEPARTMENT OF ECONOMIC AFFAIRS (FDEA)

Switzerland